Navigation Links
Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps
Date:3/28/2008

National survey reveals room for improvement in balancing seizure control

and medication-related side effects

WASHINGTON, March 28 /PRNewswire/ -- On the heels of the nation's largest event dedicated to the epilepsy community, the National Walk for Epilepsy, advocates today announced their recommendations in response to a new national survey uncovering key challenges facing the epilepsy community. Challenges include gaps in patient-physician communication around medication-related side effects and low public awareness of epilepsy.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080328/CLF099)

According to the survey, sponsored by ORTHO-McNEIL NEUROLOGICS(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., 75 percent of epilepsy patients experience medication-related side effects and for the majority, these impact their daily lives, including 57 percent who say work or school are affected. A disconnect exists between patients and healthcare professionals surrounding their discussions on these side effects. While 98 percent of physicians report discussing medication-related side effects with patients, less than half (47 percent) of epilepsy patients report these discussions take place. And, more than one-quarter of patients report they sometimes feel reluctant to broach this topic during office visits. Not surprisingly, healthcare professionals underestimate the number of patients experiencing medication-related side effects, estimating this figure at just 43 percent. The most common side effects according to the survey are fatigue, poor memory, weight gain or weight loss and loss of concentration.

"These findings suggest treatment expectations among epilepsy patients are simply too low. According to the survey, 61 percent of people with epilepsy believe that side effects are just something they have to live with," said roundtable
'/>"/>

SOURCE ORTHO-McNEIL NEUROLOGICS
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. AutismOnline.org Partners With Leading Health Communications Firm for Support
2. NYU dental researchers find evidence of periodontal disease leading to gestational diabetes
3. Leading Health Groups Applaud Continued Efforts to Protect Public Health by Ending So-Called Theatrical Productions in Bars
4. Leading Autism Expert Kenneth A. Bock, M.D. Launches National Foundation to Provide Financial Assistance to Children with Autism, Allergies, Asthma and ADHD
5. Australias Leading Juice Company Launches Juice Blend with Marteks lifesDHA(TM)
6. Researchers develop a method to select eggs with the best chance of leading to successful pregnancy
7. Leading researchers honored for progress in cancer prevention, detection and treatment
8. Following School Suicide, National Childrens Charity Issues Tips and Free Resources to Help Prevent 3rd Leading Cause of Death Among Youth
9. Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel
10. Leading Arizona Radiological Group Selects MedQuist for Speech Recognition Solution
11. Leading Health Groups Strongly Support the Minnesota Department of Healths Efforts to Enforce Freedom to Breathe Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...HINGTON, July 25 /PRNewswire/ -- Klafter & Olsen L...Care Corporation ("ArthroCare" or the,"Company") (... U.S. District,Court for the Western District of T...hased the common stock ArthroCare from January 24,...chaser Class Period") and all,persons or entities ...
(Date:7/25/2008)...ASANTON, Calif., July 25 /PRNewswire-FirstCall/ --...der in device-based mechanical,circulatory support...arts,today announced that it will report its oper... months of fiscal 2008 on Thursday, July 31., The...s financial,results and operating activities to al...
(Date:7/25/2008)...ROOK, Ill. July 25, 2008 The American Society f...idelines on the role of endoscopy in the bariatric... in the United States and the success in surgical ...er of weight-loss surgeries performed in the U.S.,...lines discuss endoscopy in the preoperative patien...
(Date:7/25/2008)...ivanCotter Releases Results of Fourth Annual Physi...urvey, DETROIT, July 25 /PRNewswire/ -- Sullivan,...rth annual survey of physician on-call pay rates a...y Report. The survey report,with data from 132 he...ian,on-call pay practices and rates paid for 33 ph...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3
...nal of Sexual Medicine examines differences in sex...m, in pre- and post-menopausal women . Participant...ed concerns regarding their own feelings of sexual...els of desire to be normal. An assessment tool wa...
...ty in the UK have discovered mutations in the DNA ...n triggering breast cancer in women . The discove...ger women at higher-than-average risk of breast ca...with mammography before they reach 50 - the age wh...
...ey see, monkey do.' Researchers at Ohio Universit...ty to see red, they began to develop red and orang...eys, such as macaques and leaf monkeys, all have t...se primates to distinguish between blue, green and...
...y quit are more likely to try kicking the habit an...t the University of Rochester . Rochester researc...edicine at the University of Rochester School of M...ew findings at a Toronto conference this month tha...
Other Medicine News:Health News:Pre- and Post-menopausal Women Responses Equally to Most Sexual Desire Cues 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 3Health News:Color Vision Drove Primates to Develop Red Skin and Hair, Study Finds 2Health News:Choice is a Key Element in Success for Smokers Who Want to Quit 2
(Date:7/23/2008)...y 23 /PRNewswire-USNewswire/ -- The following was,...rman Conyers, Ranking Member Smith, and Members of...estify today., Since I appeared before this Commi...ter acquainted with the talented and dedicated pro...work they do, and I have come to,appreciate that m...
(Date:7/23/2008)...3 /- Dendreon Corporation,(...e Independent Data,Monitoring Committee (IDMC) to ...rall survival relating to the Company,s Phase 3 IM...eatment, also known as D9902B) clinical trial,of P...,s investigational,active cellular immunotherapy f...
(Date:7/22/2008)...ly 22 /- Nonin Medical, a leading inn...ore than 20 years, has entered,the clinical testin...e,regional oxygen saturation. Today,s most common ...monitoring of the regional blood oxygenation,in th... and outcomes from an ongoing clinical study at th...
(Date:7/22/2008)... PET Study Confirms Tyrima Exhibits Excellent Drug... - Results Support Initiation of Phase II Clini...22 /- CeNeRx BioPharma,Inc., a clini...nnovative,treatments for diseases of the central n...s lead candidate Tyrima(TM) into Phase II trials f...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Study examines cold medication use in young children 20744 1Study examines cold medication use in young children 20744 2Living fossils have long and short term memory 3492 1Mutual Protection Trust Earns Third A+ Rating From A M Best 20741 1Mutual Protection Trust Earns Third A+ Rating From A M Best 20741 2U S News Ranks Cincinnati Childrens Among Top Three U S Childrens Hospitals 20738 1U S News Ranks Cincinnati Childrens Among Top Three U S Childrens Hospitals 20738 2U S News Ranks Cincinnati Childrens Among Top Three U S Childrens Hospitals 20738 3
...al of SNS-595 in Acute,Leukemia Demonstrates Addit...f., June 11, 2007,/PRNewswire-FirstCall/ -- Sunesi...om clinical studies of two of the company,s,anti-c...the 12th,Congress of the European Hematology Assoc... from Sunesis, Phase 1 Study of SNS-595 in Acute,L...
...un 11, 2007 - Geron,Corporation (Nasdaq:GERN) toda...ndicating that GRNOPC1, the company,s human,embryo...atment of,spinal cord injury, evades a direct atta... scientist Ross Okamura at the Federation of,Clini... findings,could mean that patients treated with GR...
Other Medicine Technology:Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark
...microscope technology that offers you much more th...s category. You will be impressed by the outstandi...n designed to make lab work as easy and safe as po...kflow. Your advantage: more time for the observati...
... advanced inverted microscope for automated live c...tion CFI60 optics, and extendible infinity design ...on, its super-nanoprecision z-axis motorized focus...for precise imaging in 3D. It's the first inverte...
... an innovative and efficient inverted routine micr...earch facility. , ,Outstanding Optical Performanc...ll magnifications. Objectives deliver superb optic...chromatic aberration free correction (CF), and top...
Medicine Products: